A lack of evidence is behind the NHS' decision to withhold a breakthrough prostate cancer drug from patients who have already been treated using another new generation drug, Nice said.
A spokeswoman for Nice said the committee were unable to "draw any conclusions" about what would happen if "milestone" enzalutamide was used by prostate cancer sufferers who had also taken abiraterone.
In the trial data provided by the manufacturer of enzalutamide none of the patients had received previous treatment with abiraterone, therefore the committee was not able to draw any conclusions about the effectiveness of enzalutamide after previous abiraterone treatment, and this is reflected in the recommendations.
We would welcome any additional data the manufacturer of enzalutamide can provide.
More top news
Makram Ali, 51, died of multiple injuries at the scene of the terror attack after a van crashed into a group of people near a mosque.
A teenager has been charged over the fatal shooting of her boyfriend in what she told police was a YouTube prank gone wrong.
The hunt for a blind WWII veteran's medals has intensified after Crimestoppers offered £5,000 for information which leads to their return.